StoneX Group’s Alzamend Neuro ALZN Stock Holding History

StoneX Group’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8	Closed	-$6.22K	–	451
2022 Q4	$6.22K	Buy	+8	New	+$11.6K	﹤0.01%	478

Other funds holding ALZN

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

StoneX Group's ALZN Position: Q1 2023 in Review

StoneX Group sold out of Alzamend Neuro (ALZN) in Q1 2023, closing a stake of 8 shares — an estimated $6.22K sold.

StoneX Group first reported a position in ALZN in Q4 2022 and held it in 1 quarter. The position peaked at $6.22K in Q4 2022. 24 funds tracked by Wall St. Rank hold ALZN as of Q1 2023.

StoneX Group reported no remaining Alzamend Neuro position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 8 Alzamend Neuro shares in Q1 2023, an estimated $6.22K.
StoneX Group first reported a position in Alzamend Neuro in Q4 2022 and held it in 1 quarter.
StoneX Group's Alzamend Neuro position peaked at $6.22K in Q4 2022.
24 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.